Retrospective analysis reveals comparable remission rates and faster recovery in elderly AML with 14-day venetoclax dosing, suggesting improved safety.
Key Points
The 14-day venetoclax regimen resulted in faster neutrophil recovery compared to the 28-day regimen, with a median of 12.5 days versus 26 days.
Comparable clinical remission rates were observed between the two dosing regimens, with rates of 57.4% for 14-day and 58.1% for 28-day venetoclax.
The study included 90 treatment-naive elderly patients with acute myeloid leukemia receiving venetoclax and azacitidine.
Findings suggest that a shorter venetoclax regimen may be beneficial for frail elderly patients who cannot handle prolonged treatment.